Oculogenex is a biopharmaceutical company based in La Habra, California, established in 2020. The company specializes in developing gene therapies specifically aimed at treating retinal disorders. Its innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced damage, which is a contributing factor to macular degeneration. By focusing on these therapies, Oculogenex aims to enhance the detection and treatment of various retinal disorders, ultimately supporting researchers in advancing novel drug solutions in this critical area of healthcare.
Iaso Therapeutics develops vaccines to improve human health and cure diseases. The company was founded in 2018 and is based in East Lansing, Michigan.
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.
MBF Therapeutics, Inc. is a clinical-stage veterinary oncology company dedicated to developing innovative therapies for dogs and cats with cancer. The company's portfolio includes targeted immunotherapies and small molecule drugs designed to disrupt tumor cell metabolism while sparing normal healthy cells. Notable products in development include MBFT-101, a combination therapy for sarcomas and lymphoma that merges a polyamine transport inhibitor with a potent enzyme inhibitor, and MBFT-102, an immunotherapy based on the tumor suppressor mda-7/IL24, which has shown promise in human cancers. Additionally, MBF Therapeutics is exploring gene-based immunotherapeutic vaccines, aiming to revolutionize cancer treatment and infectious disease prevention in companion animals and livestock. The company collaborates with the Lankenau Institute for Medical Research and is headquartered in Ambler, Pennsylvania.
Akttyva Therapeutics focuses on developing targeted therapeutics aimed at addressing cell barrier dysfunction, particularly in vascular barrier disorders. The company leverages its understanding of biological pathways, along with artificial intelligence and machine learning, to design innovative treatments. By concentrating on the structural aspects of cell barriers, Akttyva Therapeutics aims to provide solutions that enable healthcare professionals to effectively manage various medical conditions related to cell barrier dysfunction.
Clairways specializes in smart lung monitoring technology designed for pharmaceutical clinical trials. The company develops a wearable digital lung monitor that captures critical respiratory metrics for individuals suffering from conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). Fitted to the body, this device employs acoustic sensors and machine learning technology to detect and characterize various respiratory metrics. The collected data is presented in an accessible format, allowing healthcare providers to easily monitor and assess patients' respiratory health over the long term.
Biochip Labs, founded in 2019 and headquartered in Cleveland, Ohio, specializes in laboratory testing services for blood disorders, particularly sickle cell disease and thalassemia. The company offers a variety of proprietary microfluidic biomarker assays that assess blood cell adhesion, red blood cell deformability, whole blood rheology, and endothelialized microfluidics. These assays are designed to evaluate the efficacy of emerging targeted and curative therapies, allowing clinicians to effectively monitor patient responses to treatment. By focusing on accurate and high-quality testing, Biochip Labs aims to advance the understanding and management of blood disorders.
Kodikaz Therapeutic Solutions is focused on advancing cancer treatment by developing targeted therapies aimed at eradicating cancers while minimizing side effects. The company utilizes its innovative Zip-Code™ Technology platform, a first-in-class delivery system that facilitates cell-specific genomic transfer for both RNA and DNA applications. Rooted in discoveries from human cancers, this platform addresses the limitations associated with traditional viral delivery methods, providing a more effective and safer alternative. Kodikaz's research generates valuable in-vitro and in-vivo data across various oncological applications, including pancreatic, myeloma, and colorectal cancers, supporting the development of curative gene transfer technologies.
TheraCea Pharma is a biotechnology company that develops precision medicine to help people with neurological disorders. TheraCea Pharma, a University of Arizona spin-off based in Tucson, developed and licensed radiochemistry technology that allows for high-efficiency and rapid fluorine-18 radiolabeling of biomolecules for clinical and research applications.
Developer of neurodiagnostic technologies intended to commercialize blood testing products. The company provides critical data that can be useful in diagnosis, monitoring and assessing therapeutic responses that help to make discoveries for brain health and diseases, enabling pharmaceutical companies and researchers to drug discovery and conduct studies in brain disease.
KovaDx focuses on improving healthcare access for individuals suffering from Sickle Cell Disease and other hemolytic anemias through an innovative point-of-care solution. The company has developed a health monitoring tool that utilizes Quantitative Phase Imaging and deep learning technology to provide affordable and easy-to-use diagnostics. This system is designed to bridge gaps in care for blood diseases, enabling better management of blood health. By offering a diagnostic and monitoring device, KovaDx aims to enhance the understanding of treatment impacts and improve patient outcomes. Ultimately, the company seeks to support individuals with Sickle Cell Disease in enhancing their overall prognosis and quality of life.
Nano PharmaSolutions improves the bioavailability of insoluble drugs using innovative, revolutionary nanoformulation. Nano PharmaSolutions offers a phase-transition technology platform that can reliably enhance the solubility of BCS 2 and BCS 4 APIs without the use of excipients (e.g. large volumes of volatile solvents) used in such processes as spray dry dispersion, hot-melt extrusion, and emulsification. Their patented technology platform deposits vaporized API onto the surface of a carrier molecule which is further processable into the full spectrum of existing dosage forms.
MedChem Partners is a medicinal chemistry CRO that specializes in developing small molecule therapeutics. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
SingletO2 Therapeutics is a biotechnology company founded in 2015 and based in New Providence, New Jersey. The company focuses on developing innovative treatments for periodontal disease by utilizing the unique properties of singlet oxygen. This advanced approach capitalizes on the bacteria-killing capabilities of singlet oxygen, enabling clinicians to effectively treat advanced stages of periodontal disease without the need for surgical intervention. Through its research and development efforts, SingletO2 Therapeutics aims to improve patient outcomes and transform the management of periodontal health.
Drive Therapeutics is a biotechnology company focused on enhancing treatments for retinal diseases. The company is developing therapeutics specifically aimed at addressing wet age-related macular degeneration and diabetic retinopathy, including diabetic macular edema. Through its innovative approach, Drive Therapeutics aims to provide more effective solutions for patients suffering from these serious eye conditions.
Paramita Therapeutics is a San Diego-based biotech company established in 2018 that specializes in developing innovative therapeutics for cancer and infectious diseases. The company employs a patented multi-functional chemical platform to facilitate the rapid transition of new therapies from the laboratory to clinical settings. By focusing on multivalent drug conjugates derived from recognized and approved molecules with established safety and toxicology profiles, Paramita Therapeutics aims to enhance patient access to effective cancer treatments and dual-function therapeutic and vaccine products.
Cordance Medical is a medical device company focused on developing innovative therapies for central nervous system (CNS) pathologies, including primary and metastatic cancers, Alzheimer's disease, and Parkinson's disease. The company has created a non-invasive ultrasound system that precisely opens the blood-brain barrier, allowing for targeted delivery of systemically administered drugs to specific brain regions. This low-power ultrasound technology aims to enhance diagnostic and therapeutic options for patients, providing a safe and effective means to address complex neurological conditions.
Avior Bio is a clinical-stage pharmaceutical company focused on developing innovative treatments for neurological conditions and pruritus in patients with liver disease. The company utilizes its proprietary Speedit™ Transmucosal Film Technology, which allows for effective drug delivery by bypassing first-pass metabolism and minimizing the production of glucuronide metabolites excreted by the kidneys. This technology aims to provide significant relief from various symptoms, including insomnia, anxiety, depression, and excoriation. With a strong management team, an experienced advisory board, and dedicated scientists, Avior Bio is well-positioned to deliver safe and effective therapeutic solutions to improve patient outcomes.
Tacit Therapeutics is a biotechnology company focused on developing RNA-targeted treatments to address genetic diseases. Founded in 2021 and based in South San Francisco, California, the company utilizes pre-existing components of human cells to create innovative, non-immunogenic methods for repairing mutated genes. By offering a broadly applicable approach to gene modification, Tacit Therapeutics aims to provide effective solutions for genetic conditions that were previously deemed untreatable, thereby enabling advancements in the treatment of devastating diseases.
JuneBrain is an early start-up company that empowers multiple sclerosis patients through the power of telemedicine. It aims to develop a wearable and non-invasive imaging device that enables multiple sclerosis patients to monitor their disease activity at home, leading to earlier detection of MS attacks and improved monitoring of treatment efficacy. Its long-term goal is to extend the use of our device into the broader neurodegenerative disease population, thus creating a pathway towards more frequent, widely-accessible monitoring of brain health.
It was founded in 2017 and is headquartered in Washington, DC.
NeuroLogic Solutions, established in 2016 and based in Baltimore, Maryland, develops advanced EEG analytic software aimed at enhancing the diagnosis and treatment of epilepsy. The company’s platform analyzes electroencephalography data to identify regions of the brain affected by seizures, which assists clinicians in diagnosing epilepsy more accurately and guiding surgical interventions. By providing insights that can lead to seizure freedom, NeuroLogic Solutions seeks to improve patient outcomes and contribute to the overall effectiveness of epilepsy care.
Current Surgical is a surgical device company that develops precise tools for the treatment of solid tumors. The company was founded in 2020 and has its headquarters in Washington, DC.
NellOne Therapeutics, Inc. is a regenerative medicine company based in Oak Ridge, Tennessee, focused on developing and commercializing protein therapeutics aimed at restoring cardiac muscle mass and function in patients recovering from myocardial infarction and congestive cardiac failure. Established in 2007 and spun out from the U.S. Department of Energy's Oak Ridge National Laboratory, NellOne's foundation is rooted in research conducted by Dr. Cymbeline Culiat, who identified the therapeutic potential of the Nell1 gene pathway in tissue regeneration. The company’s primary goal is to translate scientific discoveries into clinical applications that improve recovery outcomes for individuals affected by heart conditions.
Precision Theranostics is a biotechnology company based in Baltimore, Maryland, founded in 2019. The company focuses on developing prognosis-based intervention strategies aimed at the early detection and treatment of fatal diseases. Its innovative platform is designed to estimate disease progression, particularly for respiratory diseases and age-related disorders. By creating novel diagnostics, therapeutics, and prognosis-based therapies, Precision Theranostics enables healthcare providers to deliver timely diagnoses and interventions, ultimately improving survival rates and preventing the progression of chronic and fatal conditions.
Epivara, founded in 2016 and based in Champaign, Illinois, is developing a single-injection alternative to traditional spaying and neutering surgeries. This innovative approach aims to provide a safer and less invasive method for sterilizing pets, eliminating the pain and risks associated with conventional surgical procedures. By utilizing a small capsule, Epivara's solution offers the benefits of neutering, such as preventing overpopulation and reducing reproduction-related diseases, while also sparing pet owners from the costs and lengthy recovery times of surgery. The company's mission centers on enhancing the well-being of animals and their owners through compassionate care and cutting-edge scientific advancements.
Oculogenex is a biopharmaceutical company based in La Habra, California, established in 2020. The company specializes in developing gene therapies specifically aimed at treating retinal disorders. Its innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced damage, which is a contributing factor to macular degeneration. By focusing on these therapies, Oculogenex aims to enhance the detection and treatment of various retinal disorders, ultimately supporting researchers in advancing novel drug solutions in this critical area of healthcare.
Enable Therapeutics
Grant in 2021
Enable Therapeutics is a biotechnology company developing a patented drug delivery platform. The company was founded in 2020 and is headquartered in Hopedale, Massachusetts.
NeyroblastGX is a biotechnology company established in 2020 and based in Murrieta, California, focused on developing theranostic products aimed at treating neurodegenerative and infectious diseases. The company’s product offerings include a blood-based biomarker diagnostic for Alzheimer's, genetically engineered dendritic cells designed to eliminate custom-made human organoids for drug screening, cellular toxicity assessment, and disease pathology. Additionally, NeyroblastGX develops an oral supplement intended to enhance protective immunity, providing patients with a comprehensive portfolio of diagnostics, drugs, and therapies to combat life-threatening conditions.
Active Therapy Systems is a company based in Nicholasville, Kentucky, founded in 2017. It specializes in developing an interactive exercise platform designed to provide in-home therapies for individuals living with Parkinson's disease. The platform aims to enhance the management of Parkinson's through personalized therapies and remote patient monitoring, allowing users to engage in activities that may help alleviate their symptoms. By focusing on the specific needs of those affected by Parkinson's, Active Therapy Systems seeks to improve their quality of life and promote greater independence in daily activities.
FibrosIX is a biotechnology company develops drugs to prevent lung fibrosis in cancer patients. The company was founded in 2016 and is headquartered in East Lansing, Michigan.
Gradient Medical develops novel interventional oncology services to bring ACE therapy to the clinic. The company was founded in 2020 and is headquartered in Raleigh, North Carolina.
Operator of a biotechnology company intended to improve research, health, and wellness by providing access to accurate and cost-effective specimen collection devices. The company's device stabilized sensitive tests and facilitates remote specimen collection, including urine, serum, plasma, or any other bodily fluid, and simple transportation at ambient temperature, enabling people in the community to access accurate and cost-effective diagnoses.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
Grit Bio develops cancer therapeutics with the goal of providing a safer approach to treating pharyngeal squamous cell carcinoma. The company was founded in 2017 and is headquartered in New York, NY.
Progenitor MDX provides a comprehensive and customizable solution to manage COVID-19 infections from start to finish. We not only deliver testing results, but also help you develop actionable plans for infection management, providing reassurance to your communities.
Akanocure's mission is to synthesize and develop biotargeted anti-cancer chemotherapeutic drugs derived from natural sources. Akanocure's pipeline will consist of analogs of fully validated, highly potent anti-cancer natural products that can only be produced on a large scale through Akanocure's proprietary CCC synthesis platform. The company has competitive edges on two fronts: the synthesis platform that gives Akanocure exclusive access to rare compounds and the potential pipeline of anti-cancer products that are far superior to existing therapies.
Creative BioTherapeutics is a biotechnology company developing therapies for cancer and viruses. The company is changing the way that cancer and viral disease research is conducted. It focuses on the root cause of cancer affecting immune evasion and drug resistance.
Ernest Pharmaceuticals is a biotechnology company based in Hadley, Massachusetts, founded in 2016. The company specializes in developing innovative bacterial therapeutics aimed at treating cancer. Its unique approach involves programming bacteria to deliver intracellular macromolecules directly into tumor tissues. These engineered bacteria are motile, allowing them to actively penetrate and target metastatic diseases and inoperable tumors. Through these advancements, Ernest Pharmaceuticals aims to enhance treatment options for patients facing challenging cancer diagnoses.
Saphtx develops protein-based therapeutic strategies for a wide range of diseases. The company was founded in 2018 and is headquartered in Newark, New Jersey.
TEGA Therapeutics, Inc. is focused on developing glycoscience-related technologies aimed at treating life-threatening diseases. Founded in 2013 and based in La Jolla, California, the company specializes in enhancing the delivery of enzyme replacement therapies to the brain, particularly for lysosomal storage disorders. By leveraging glycoside-enhanced delivery methods, TEGA addresses significant challenges in reaching the central nervous system, thereby improving treatment outcomes. Additionally, the company produces bio-engineered heparan sulfate and heparin, which play crucial roles in various physiological processes. TEGA's mission is to improve the quality of life for patients by providing innovative solutions for unmet medical needs, utilizing rigorous scientific methods to advance the therapeutic potential of glycans in medicine.
Omnicyte is a biotechnology company focused on developing targeted treatments for cancer therapy. It utilizes a proprietary Immuno-Oncology Platform Technology to create recombinant targeted immunomodulators aimed at addressing unmet medical needs in oncology. The company is actively working on treatments for various cancer indications, including ovarian cancer and small cell lung cancer. By advancing its innovative platform, Omnicyte aims to enhance patient outcomes and improve quality of life for individuals affected by these challenging diseases.
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision’s CLIA-certified, central laboratory in Pittsburgh. Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.
Lapovations is a healthcare company focused on the development of innovative medical devices for laparoscopic surgery. Established in 2016 and headquartered in Fayetteville, Arkansas, the company aims to redefine the field of laparoscopy by creating products that minimize invasiveness and simplify surgical procedures. Their medical devices are designed to enhance surgical outcomes, allowing medical professionals to perform surgeries with increased safety and efficiency.
Thermaquil, Inc. develops and sells medical devices to control pain and other conditions caused by overactive nerves. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
Cactus Medical provides physicians with a standardized method for evaluating middle ear effusion. The company was founded in 2017 and is headquartered in Irvine, California.
Jupiter Therapeutics is a biotechnology company specializing in the development of cell-membrane-based therapeutics. The company employs a synthetic biology approach to rapidly design and synthesize a diverse pipeline of therapeutic assets targeting cancer, autoimmune diseases, drug delivery, and gene therapy. By utilizing advanced cell engineering techniques, Jupiter Therapeutics creates customized vesicles that enhance immuno-oncology applications and gene therapy strategies. This innovative approach allows medical researchers to leverage insights gained from cell-membrane studies to improve treatments involving CAR T-cells and bi-specific antibodies.
Travera, LLC operates in the biotechnology industry. The company uses Suspended Microchannel Resonator device to measure change in the weight of a single cancer cell called Mass Accumulation Rate (MAR) biomarker to determine which drugs to prescribe based on the actual responses of their patients’ tumor cells to candidate drugs. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts.
Inherent Biosciences is a molecular diagnostics company that revolutionizes trial and error medicine and restore hope. The company does this by discovering what's inherent in our biology about the unexplained and translating discoveries into personal insights that inform actions. Inherent Biosciences develops medicines for treating pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, COVID-19, and many more.
VerImmune, based in Baltimore, Maryland, is an immuno-oncology company focused on developing innovative cancer therapies through a unique approach called Anti-tumor Immune Redirection. The company employs proprietary virus-inspired particles, known as Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs), which harness pre-existing immune memory from past infections or childhood vaccinations to target tumors. This strategy aims to offer a new treatment option for patients with limited alternatives or those who have developed resistance to conventional cancer therapies. VerImmune's technology seeks to deliver low toxicity and sustainable benefits across a wide array of cancers, potentially reshaping the treatment landscape for difficult-to-treat cases.
New Equilibrium Biosciences focuses on the research and development of therapeutic drugs aimed at treating cancer, neurodegenerative diseases, and other medical conditions. The company specializes in targeting intrinsically disordered proteins (IDPs), which play a significant role in various disorders. By integrating artificial intelligence with quantum chemistry, New Equilibrium leverages biophysical experiments to explore opportunities for structure-based drug design. This approach includes the creation of compound libraries specifically for IDPs, allowing for the identification of potential drug candidates that can interact with transient binding pockets on these proteins. Through its innovative platform, New Equilibrium aims to enhance drug discovery processes and improve treatment options within the healthcare sector.
Developer of clinical trial software designed to provide image data management for clinical trials. The company's platform provides file transfer and verification, integration with clinical data, automation of image processing routines and connectivity, helping health professionals with clinical research and diagnostics.
Caza Health is a biotech company specializing in the microbiome, immunology, and oncology. The company was founded in 2019 and is headquartered in Earlysville, Virginia.
Intact Therapeutics designs and develops a thermosensitive drug delivery platform for the treatment of gastrointestinal (GI) disorders. The company was founded in 2015 and is based in Belmont, California.
Koya Medical, Inc. is a company based in Oakland, California, founded in 2018. It focuses on developing a connected wearable platform designed to address the significant unmet needs in the treatment of cancer-related chronic lymphedema and venous diseases. The technology aims to provide a drug-free solution for patients suffering from these conditions, enhancing their quality of life through innovative medical devices.
Chosen Diagnostics specializes in developing innovative biomarker diagnostic kits aimed at enhancing healthcare delivery for neonates. The company’s primary product is a test designed to diagnose a serious and potentially life-threatening bowel disease in preterm infants. This diagnostic kit provides more accurate results compared to existing methods, facilitating earlier medical intervention. By enabling timely detection of critical health issues, Chosen Diagnostics aims to improve treatment outcomes for thousands of low birth weight preterm infants, ultimately leading to better healthcare results in this vulnerable population.
AxonDx specializes in the detection and characterization of circulating tumor cells (CTCs) in the bloodstream, which serve as critical indicators of solid tumors and their metastases. The company has developed the nCYTE™ technology, a rapid and highly accurate system that scans un-enriched blood samples in minutes, identifying all classes of CTCs shed by solid tumors. This innovative approach not only provides morphological insights into the CTCs but also allows for outsourced molecular characterization, facilitating more personalized and effective cancer treatment. Unlike existing CTC detection methods, which are often slow, expensive, and less sensitive, nCYTE™ is designed to be compact and cost-effective, making it suitable for point-of-care applications. AxonDx operates on a "razor and blade" business model, selling nCYTE™ instruments along with diagnostic kits, thereby promoting widespread adoption of its game-changing technology in cancer diagnostics.
Cordance Medical is a medical device company focused on developing innovative therapies for central nervous system (CNS) pathologies, including primary and metastatic cancers, Alzheimer's disease, and Parkinson's disease. The company has created a non-invasive ultrasound system that precisely opens the blood-brain barrier, allowing for targeted delivery of systemically administered drugs to specific brain regions. This low-power ultrasound technology aims to enhance diagnostic and therapeutic options for patients, providing a safe and effective means to address complex neurological conditions.
LEAH Laboratories specializes in developing innovative gene-editing technologies aimed at treating cancer in dogs, particularly B-cell lymphoma. The company utilizes precision gene editing to reprogram T immune cells with Chimeric Antigen Receptors (CAR), creating CAR T cells that can specifically target and eliminate cancerous cells while minimizing off-target effects commonly associated with traditional chemotherapy. By harnessing the natural capabilities of the canine immune system, LEAH Laboratories provides a novel approach to cancer treatment, offering hope to pet owners and veterinarians in their fight against this challenging disease. Based in the United States, LEAH Labs is committed to advancing medical therapies for canine health.
Akanocure's mission is to synthesize and develop biotargeted anti-cancer chemotherapeutic drugs derived from natural sources. Akanocure's pipeline will consist of analogs of fully validated, highly potent anti-cancer natural products that can only be produced on a large scale through Akanocure's proprietary CCC synthesis platform. The company has competitive edges on two fronts: the synthesis platform that gives Akanocure exclusive access to rare compounds and the potential pipeline of anti-cancer products that are far superior to existing therapies.
Haima Therapeutics is a pre-clinical stage biotechnology company. It focused on developing bio-inspired therapies for the treatment of bleeding and other blood-related ailments. They developed a novel, nanoparticle-based synthetic hemostatic technology, called SynthoPlate, that can staunch hemorrhagic bleeding by binding to the site of injury and amplifying your body’s natural clotting mechanisms. It was founded in 2016 and is headquartered in Cleveland, Ohio.
Triangle Biotechnology is a biotechnology company dedicated to advancing research through innovative sample preparation solutions. The firm specializes in technologies that enhance biological sample workflows, particularly in the areas of DNA sharing for next-generation sequencing, chromatin shearing for chromatin immunoprecipitation (ChIP), and cell lysis. By utilizing efficient acoustic processing methods, Triangle Biotechnology aims to streamline the preparation of biological samples, thereby facilitating more effective research outcomes.
Envivo Bio develops a non-invasive device that collects microbiome samples from all regions of the human gastrointestinal tract. The company is based in San Carlos, California.
Amberstone Biosciences specializes in the discovery of novel immunotherapies aimed at addressing unmet medical needs through advanced technologies and strategic collaborations. The company focuses on challenging therapeutic targets that require unique mechanisms of action, which traditional methods struggle to tackle. Amberstone employs a microfluidics-powered drug discovery platform, known as AmberFlow, to analyze single-cell functions within a customizable microenvironment. This innovative approach allows for a more precise understanding of immune responses, enabling the development of transformative therapeutic antibodies. The team's expertise in immuno-oncology and single-cell assay biology further enhances their capacity to create effective treatments, ultimately improving patient outcomes.
Zenobia Therapeutics, founded in 2008, specializes in developing treatments for neurodegenerative diseases through fragment-based lead discovery. The company employs fragment-based therapies to create innovative medical treatments and offers a dedicated division, Zenobia Fragments, which supplies products and services designed to support researchers in target validation and lead discovery programs. By providing these tools, Zenobia Therapeutics enables researchers to advance their efforts in discovering effective treatments for neurology-related diseases.
Developer of a novel drug therapy designed to treat and prevent recurrent kidney stones. The company's therapy is derived from a gut bacterium to prevent and treat kidney stone diseases such as hyperoxaluria and oxalate-based kidney stones as well as renal diseases caused by high levels of oxalate in the body, thereby enabling patients to receive quality drug therapy in order to remove oxalate safely from the body and consequently prevent recurrence of stones.
Thermaquil, Inc. develops and sells medical devices to control pain and other conditions caused by overactive nerves. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.
Design Therapeutics, Inc. is a clinical-stage biotechnology company based in Solana Beach, California, focused on developing innovative therapies for degenerative disorders resulting from nucleotide repeat expansions. Founded in 2017, the company is advancing its lead program aimed at treating Friedreich's ataxia, while also exploring treatment options for other conditions such as Fragile X syndrome and myotonic dystrophy. Design Therapeutics is known for its GeneTACTM molecules, a new class of small-molecule gene-targeted therapies designed to address the underlying causes of diseases linked to inherited nucleotide repeat expansion mutations. The company's ongoing research efforts seek to develop disease-modifying treatments for serious conditions driven by these genetic factors.
Iaso Therapeutics develops vaccines to improve human health and cure diseases. The company was founded in 2018 and is based in East Lansing, Michigan.
Lapovations is a healthcare company focused on the development of innovative medical devices for laparoscopic surgery. Established in 2016 and headquartered in Fayetteville, Arkansas, the company aims to redefine the field of laparoscopy by creating products that minimize invasiveness and simplify surgical procedures. Their medical devices are designed to enhance surgical outcomes, allowing medical professionals to perform surgeries with increased safety and efficiency.
Sanguine Biosciences, Inc. provides customizable specimen collection services across the United States, maintaining a biorepository of frozen samples from donors with various disease conditions. The company specializes in same-day collection and shipment of time-sensitive blood samples, ensuring that patient samples meet specific study requirements, including demographics and medical history. Sanguine supports clinical and pharmacogenomic studies by offering comprehensive biomaterials storage, sample collection with preferred anticoagulants, and the ability to aliquot samples into suitable volumes. The company collaborates with numerous U.S.-based clinics and hospitals for longitudinal studies and also offers products online. Founded in 2010 and located in Sherman Oaks, California, Sanguine utilizes innovative technology solutions to facilitate clinical trials, including participant recruitment and at-home data collection, thereby aiding clinicians in prescribing appropriate treatments.
Travera, LLC operates in the biotechnology industry. The company uses Suspended Microchannel Resonator device to measure change in the weight of a single cancer cell called Mass Accumulation Rate (MAR) biomarker to determine which drugs to prescribe based on the actual responses of their patients’ tumor cells to candidate drugs. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts.
Developer of novel inhibitors of protein interactions intended for therapeutic purposes. The company specializes in the discovery of inhibitors through peptidomimetic binders that recognize the targeted interference of disease-causing proteins for the treatment of cancer, autoimmune disorders, infectious illnesses and other related diseases allowing them to target both intracellular and extracellular targets, enabling clients to discover drugs and treat severe medical conditions.
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes proprietary technology to deliver therapeutic DNA directly to intestinal stem cells, aiming to address the underlying causes of diseases such as Familial Adenomatous Polyposis (FAP), a hereditary form of colorectal cancer that often necessitates invasive surgical procedures. By targeting these root causes, DNALite seeks to prevent disease progression rather than merely managing symptoms, offering a potentially transformative approach to treating gastrointestinal disorders, including colorectal cancer and Crohn's disease.
TEGA Therapeutics, Inc. is focused on developing glycoscience-related technologies aimed at treating life-threatening diseases. Founded in 2013 and based in La Jolla, California, the company specializes in enhancing the delivery of enzyme replacement therapies to the brain, particularly for lysosomal storage disorders. By leveraging glycoside-enhanced delivery methods, TEGA addresses significant challenges in reaching the central nervous system, thereby improving treatment outcomes. Additionally, the company produces bio-engineered heparan sulfate and heparin, which play crucial roles in various physiological processes. TEGA's mission is to improve the quality of life for patients by providing innovative solutions for unmet medical needs, utilizing rigorous scientific methods to advance the therapeutic potential of glycans in medicine.
Clairways specializes in smart lung monitoring technology designed for pharmaceutical clinical trials. The company develops a wearable digital lung monitor that captures critical respiratory metrics for individuals suffering from conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). Fitted to the body, this device employs acoustic sensors and machine learning technology to detect and characterize various respiratory metrics. The collected data is presented in an accessible format, allowing healthcare providers to easily monitor and assess patients' respiratory health over the long term.
Cactus Medical provides physicians with a standardized method for evaluating middle ear effusion. The company was founded in 2017 and is headquartered in Irvine, California.
Developer of fast-tracking drugs designed to treat genetic diseases with a focus on Huntington's Disease. The company's drugs are discovered through its proprietary human stem cell technology that uses single-cell, time-lapse imaging and customized analytic tools to inexpensively and effectively identify treatments for human genetic diseases, enabling patients to receive improved treatment success rates, speedy drug development, and enhanced outcomes.
The Mednet is a community of physicians helping each other treat patients with cancer.Their Mission is Improve knowledge sharing between physicians so that patients get high quality care wherever they are treated.They help physicians get answers to questions where there is no clear answer in guidelines or published research and expert opinion is necessary. All answers are indexed and searchable so that every physician can quickly access expert knowledge to provide their patients with high quality care.
Cell Reprogramming & Therapeutics, founded in 2013 and based in Wauwatosa, Wisconsin, specializes in developing innovative cell reprogramming technologies aimed at treating central nervous system diseases. These technologies facilitate the generation of stem cell lines and specific differentiated cell types from patients' somatic cells, which can be utilized for disease modeling, toxicity screening, and drug discovery. By enabling researchers to create advanced cellular models, the company contributes to the development of therapeutics for various neurological disorders, thereby opening new avenues for treatment and enhancing understanding of these complex conditions.
NeuroPrex is developing a non-invasive magnetic stimulation device with shield protection and deeper energy delivery for treating major depression and other neurological disorders. Its product will be able to deliver more healing eddy currents to a patient’s disorders with less patient discomfort than other designs. In addition, the cost of the device and treatment cost is expected to be materially lower than for other devices. NeuroPrex wants to change things. The company believes that people deserve better treatment plans than options between a rock and a hard place.
Developer of advanced quantload technology designed for producing super-extended-release formulations of weak-base, small-molecule drugs. The company's lipid nanoparticle technology offers, stimulants for treating ADHD, anti-HIV drugs, antibiotics, antipsychotics, cancer chemotherapy agents, antihistamines, and analgesics, enabling the healthcare industry to improve human health.
Insera Therapeutics is a developer of medical devices focused on treating neurovascular diseases, which are significant contributors to disability and mortality worldwide. The company's innovative devices are engineered to navigate through brain vessels, effectively collecting clots, fat deposits, and debris. This minimally invasive approach allows physicians to address various neurovascular conditions more efficiently, ultimately improving patient outcomes. With the prevalence of stroke affecting over 700,000 individuals annually in the United States alone, Insera Therapeutics aims to provide effective solutions that enhance treatment options for these critical health issues.
JuneBrain is an early start-up company that empowers multiple sclerosis patients through the power of telemedicine. It aims to develop a wearable and non-invasive imaging device that enables multiple sclerosis patients to monitor their disease activity at home, leading to earlier detection of MS attacks and improved monitoring of treatment efficacy. Its long-term goal is to extend the use of our device into the broader neurodegenerative disease population, thus creating a pathway towards more frequent, widely-accessible monitoring of brain health.
It was founded in 2017 and is headquartered in Washington, DC.
Active Therapy Systems is a company based in Nicholasville, Kentucky, founded in 2017. It specializes in developing an interactive exercise platform designed to provide in-home therapies for individuals living with Parkinson's disease. The platform aims to enhance the management of Parkinson's through personalized therapies and remote patient monitoring, allowing users to engage in activities that may help alleviate their symptoms. By focusing on the specific needs of those affected by Parkinson's, Active Therapy Systems seeks to improve their quality of life and promote greater independence in daily activities.
Ernest Pharmaceuticals is a biotechnology company based in Hadley, Massachusetts, founded in 2016. The company specializes in developing innovative bacterial therapeutics aimed at treating cancer. Its unique approach involves programming bacteria to deliver intracellular macromolecules directly into tumor tissues. These engineered bacteria are motile, allowing them to actively penetrate and target metastatic diseases and inoperable tumors. Through these advancements, Ernest Pharmaceuticals aims to enhance treatment options for patients facing challenging cancer diagnoses.
Iria Pharma develops cancer targeting and drug delivery technology to provide a platform for targeted cancer therapeutics. The company was founded in 2016 and is based in Champaign, Illinois.
Developer of novel painless therapies designed to treat dangerous cardiac arrhythmias and other disorders. The company develops technology for the painless prevention and termination of dangerous cardiac arrhythmias with therapies focus on atrial fibrillation, enabling patients to get treatment for irregular heartbeats painlessly.
Enable Biosciences is biotech company making ultrasensitive tests for HIV, type 1 diabetes, and many other diseases. They develop ultrasensitive immunoassays that permit early detection and treatment of autoimmune and infectious diseases.
Akanocure's mission is to synthesize and develop biotargeted anti-cancer chemotherapeutic drugs derived from natural sources. Akanocure's pipeline will consist of analogs of fully validated, highly potent anti-cancer natural products that can only be produced on a large scale through Akanocure's proprietary CCC synthesis platform. The company has competitive edges on two fronts: the synthesis platform that gives Akanocure exclusive access to rare compounds and the potential pipeline of anti-cancer products that are far superior to existing therapies.
Haima Therapeutics is a pre-clinical stage biotechnology company. It focused on developing bio-inspired therapies for the treatment of bleeding and other blood-related ailments. They developed a novel, nanoparticle-based synthetic hemostatic technology, called SynthoPlate, that can staunch hemorrhagic bleeding by binding to the site of injury and amplifying your body’s natural clotting mechanisms. It was founded in 2016 and is headquartered in Cleveland, Ohio.
Senti Biosciences is a clinical-stage biotechnology company based in South San Francisco, California, focused on developing innovative gene and cell therapies using its proprietary synthetic biology platform. Founded in 2016, the company aims to address complex diseases through advanced therapeutic solutions. Senti's technology includes engineered allogeneic chimeric antigen receptor natural killer (CAR-NK) cells, which are designed to target and eliminate cancer cells while minimizing damage to healthy tissue. Among its product candidates are SENTI-202, a Logic Gated CAR-NK cell therapy intended for cancer treatment, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences operates as a resident company at Johnson & Johnson Innovation's JLABS in South San Francisco, collaborating with experts in synthetic biology and computation to advance its therapeutic developments.
PathoVax LLC is a biotechnology company based in Baltimore, Maryland, founded in 2014. It focuses on the development of RGVax, an innovative vaccine designed to protect against human papillomavirus (HPV). RGVax is notable for being the first low-cost HPV vaccine that targets all clinically relevant types, including all 15 oncogenic strains and additional skin HPV types. This broad-spectrum approach addresses the limitations of existing vaccines, which primarily focus on a limited number of cancer-causing strains and often face low uptake due to incomplete coverage and associated social stigma. Established animal studies have demonstrated the protective efficacy of RGVax, positioning it as a suitable childhood vaccine and offering the potential for significant early market entry in a segment that could see higher acceptance and usage rates.
Micro-Leads Medical is a medical technology company focused on creating innovative therapies within the neuromodulation and bioelectronic medicine sectors. The company has developed a wireless implantable neuromodulation device that delivers arbitrary bi-phasic pulses and kilohertz blocking patterns. This platform allows for wireless programming of stimulation patterns via a browser interface, utilizing subcutaneous, implantable peripheral nerve stimulators. Its offerings include features such as tether-free animal operation, adjustable anodic and cathodic amplitudes, and unobtrusive wireless charging accessories. These advancements aim to enhance spinal-cord stimulation therapy, providing relief for patients suffering from back pain and related disorders.
Developer of infectious disease assays with a core expertise for quantitation of low-frequency viral targets intended to detect inactive human immunodeficiency viruses in the blood. The company's technology uses a medical device and diagnostic tool to accurately measure the size of the latent reservoir by quantifying the number of intact viruses, enabling physicians to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical and reservoir measurements for the advancement of HIV-1 cure trials.
iVeena Delivery Systems, Inc. is a biopharmaceutical company based in Salt Lake City, Utah, specializing in ophthalmology products. Founded in 2006 by Bala Ambati, the company focuses on developing innovative therapies for various ocular conditions. Its product line includes IVMED-10, IVMED-20, IVMED-80, and IVMED-85, which are aimed at treating post-cataract inflammation and pediatric myopia. Additionally, iVeena is engaged in research and development of novel drug candidates targeting conditions such as macular degeneration, diabetic retinopathy, and glaucoma. The company employs a unique drug delivery platform designed to enhance the ocular bioavailability of medications, facilitating effective treatment for both anterior and posterior segments of the eye. Currently, iVeena has several products in the late pre-clinical and research phases, focusing on advanced therapeutic solutions for ophthalmic diseases.
Developer of novel cancer therapeutics and therapies designed to make cancer treatments more predictable. The company's services deliver beneficial therapeutics to patients suffering from cancer and other serious illnesses and also a novel drug conjugate approach that uses computationally designed affinity tags to drive therapeutic compounds into cancer cells and has a pipeline of conjugated anti-cancer compounds with payloads specific to a variety of clinically-relevant targets including kinase inhibitors, enzyme inhibitors, and cell cycle inhibitors, enabling patients to get proper treatment for cancer without any side effects
AivoCode Inc. is a biotechnology company specializing in the treatment and management of critical neurological diseases, including brain injury and Alzheimer's disease. The company has developed proprietary peptides that can specifically identify molecular changes associated with these conditions. These peptides enhance the delivery of various therapeutics and diagnostic agents directly to affected areas of the brain, improving both therapeutic efficacy and non-invasive detection methods. AivoCode's technology aims to facilitate site-specific drug delivery, thereby enabling better recognition and treatment of Alzheimer's disease and other neurodegenerative disorders. The development of AivoCode's technology has been supported entirely through non-dilutive federal grant funding.
Humonix Biosciences is a biotechnology company focused on reducing the cost of ophthalmic drug development through innovative platform technology. Established in 2014 and based in Albany, New York, the company offers a comprehensive range of services including drug screening and discovery, dose response analysis, biological and physiological assessments, as well as safety and toxicity evaluations. Utilizing a 3D tissue system, Humonix aims to provide physiologically relevant data that enhances the drug development process, helping to identify and validate effective compounds and biologics. This technology supports clients in accelerating their drug development efforts, ultimately increasing confidence in the success of clinical trials.
Histogen Inc. is a clinical-stage regenerative medicine company based in San Diego, California, established in 2007. The company specializes in developing therapies using cell products cultivated under simulated embryonic conditions, aiming to stimulate the body's own stem cells. Histogen's product portfolio includes human multipotent cell conditioned media, human extracellular matrix, and hair stimulating complex. The company focuses on creating biologic products that do not involve embryonic stem cells or animal components. Its proprietary technology leverages bioreactors to produce vital proteins and growth factors, leading to the development of two primary product families: a liquid complex of embryonic-like proteins and a human extracellular matrix material called ExCeltrix. Additionally, Histogen is advancing product candidates such as HST-003 for joint cartilage repair and HST-004 for spinal disc repair, along with a pipeline of small molecule inhibitors targeting infectious and inflammatory diseases.